IRX-2 increases the T cell-specific immune response to protein/peptide vaccines

Vaccine

Volumn 28, Issue 43, 2010, Pages 7054-7062

  Naylor, Paul H ^a   Hernandez, Karla E ^a   Nixon, April E ^a   Brandwein, Harvey J ^a   Haas, Gabriel P ^b   Wang, Ching Y ^b   Hadden, John W ^a  

^a IRX Therapeutics Inc   (United States)

^b SUNY UPSTATE MEDICAL UNIVERSITY   (United States)

Author keywords

Adjuvants; Aging; Cytokines; IRX 2; Prostate specific membrane antigen; Vaccine

Indexed keywords

ADJUVANT; CANCER VACCINE; FREUND ADJUVANT; GAMMA INTERFERON; IMMUNOMODULATING AGENT; IRX 2; NFT PEPTIDE; PEPTIDE VACCINE; POLYSORBATE 80; PROSTATE SPECIFIC MEMBRANE ANTIGEN; SQUALENE; TREHALOSE DICORYNOMYCOLATE PLUS MONOPHOSPHORYL LIPID A; UNCLASSIFIED DRUG;

ANIMAL EXPERIMENT; ANTIBODY TITER; ARTICLE; B LYMPHOCYTE; CELL ACTIVITY; CELL EXPANSION; DELAYED HYPERSENSITIVITY; DRUG POTENCY; HUMAN; IMMUNE RESPONSE; IMMUNOREACTIVITY; LYMPH NODE; MOUSE; NONHUMAN; PRIORITY JOURNAL; PROTEIN EXPRESSION; PROTEIN SECRETION; SPLEEN; T LYMPHOCYTE; TUMOR GROWTH;

3T3 CELLS; ADJUVANTS, IMMUNOLOGIC; ANIMALS; CANCER VACCINES; CYTOKINES; FEMALE; HUMANS; INTERFERON-GAMMA; MICE; MICE, INBRED BALB C; PROSTATE-SPECIFIC ANTIGEN; T-LYMPHOCYTES; VACCINES, SUBUNIT;

EID: 77957349186     PISSN: 0264410X     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.vaccine.2010.08.014     Document Type: Article

References (34)

1. Berinstein N.L. Strategies to enhance therapeutic activity of cancer vaccines: using melanoma as a model. NYAS 2009, 1174:107-117.
2. McNeel D.G. Cellular immunotherapies for prostate cancer. Biomed Pharmacother 2007, 61:315-322.
3. Drake C.G. Basic overview of current immunotherapy approaches in urologic malignancy. Urol Oncol: Semin Orig Invest 2006, 24:413-418.
4. Finke H.L., Wentworth K., Blumenstein B., Rudolph N.S., Levitsky H., Hoos A. Lessons from randomized phase III studies with active cancer immunotherapies. Vaccine 2007, B97-109.
5. Palena C., Abrams S.I., Schlom J., Hodge J.W. Cancer Vaccines: preclinical studies and novel strategies. Adv Cancer Res 2006, 115-145.
6. Henderson R.A., Mossman S., Narin N., Cheever M.A. Cancer vaccines and immunotherapies: emerging perspective. Vaccine 2005, 23:2359-2362.
7. Schlom J., Gullley J.L., Arlen P.M. Paradigm shifts in cancer vaccine therapy. Exp Biol Med 2008, 233:522-534.
8. Naylor P.H., Hadden J.W. T cell targeted immune enhancement yields effective T cell adjuvants. Int J Immunopharmacol 2003, 3:1205-1215.
9. Hadden J.W., Endicott J., Baekey P., Skipper P., Hadden E.M. Interleukins and contrasuppression induce immune regression in head and neck cancer. Archotolaryngol Head Neck Surg 1994, 120:395-403.
10. Freeman SM, Franco JLB, Kenady DE, Baltzer L, Roth Z, Brandwein HJ et al. A phase 1 safety study of an IRX-2 regimen in patients with squamous cell carcinoma of the head and neck. Am J Clin Oncol, in press. doi:10.1097/COC.0b013e3181dbb9d8.
11. Egan J., Quadrini K., Santiago-Schwarz F., Hadden J., Brandwein H., Signorelli K. IRX-2, a novel in vivo immunotherapeutic, induces maturation and activation of human dendritic cells in vitro. J Immunother 2007, 6:624-633.
12. Meneses A., Verastegui E., Barrera J.L., Garza J., Hadden J.W. Lymph node histology in head and neck cancer: impact of immunotherapy with IRX-2. Int Immunopharm 2003, 3:1073-1082.
13. Hadden J.W., Verastegui E., Barrera J.L., Kurman M., Meneses A., Zinser J.W., et al. A trial of IRX-2 in patients with squamous cell carcinomas of the head and neck. Int Immunopharm 2003, 3:1083-1091.
14. Durso R.J., Andjelic S., Gardner J.P., Margitich D.J., Donovan G.P., Arrigale R.R., et al. A novel alphavirus vaccine encoding prostate-specific membrane antigen elicits potent cellular and humoral immune responses. Clin Cancer Res 2007, 12:3999-4008.
15. Sweat S.C., Pacelli A., Murphy G.P., Bostwick D.G. Prostate-specific membrane antigen (PSMA) expression is greatest in prostate adenocarcinoma and lymph node metastases. Urology 1998, 52:637-640.
16. Toja B.A., Murphy G.P. Development of dendritic-cell based prostate cancer vaccine. Immunol Lett 2000, 74:87-93.
17. Toja B.A., Simmons S.J., Bowe V.A., Ragde H., Rogers M., Elgamal A., et al. Evaluation of phase I/II clinical trials in prostate cancer with dendritic cells and PSMA peptides. Prostate 1998, 36:39-44.
18. Katsuyuki K., Nishisaka N., Jones R.F., Wang C.Y., Haas G.P. Clinical trials of immunotherapy for advanced prostate cancer. Urol Oncol 2000, 5:265-273.
19. Bacich D.J., Pinto J.T., Tong W.P., Heston W.D. Cloning, expression, genomic localization and enzymatic activity of the mouse homomolog of prostate-specific membrane antigen/NAALADase/folate hydrolase. Mamm Genome 2001, 12:117-123.
20. Kuratsukuri K., Sone T., Wang C.Y., Nishisaka N., Jones R.F., Haas G.P. Inhibition of prostate-specific membrane antigen (PSMA)-positive tumor growth by vaccination with either full-length or the C-terminal end of PSMA. Int J Cancer 2002, 102:244-249.
21. Baldridge J.R., Ward J.R. Effective adjuvants for the induction of antigen specific delayed-type hypersensitivity. Vaccine 1997, 15:395-401.
22. Black C.A. Delayed type hypersensitivity: current theories with an historic perspective. Dermatol Online J 1999, 5:7-10.
23. Mosmann T.R., Sad S. Functions of CD8 T-cell subsets secreting different cytokine patterns. Semin Immunol 1997, 8:87-92.
24. Vacca A., Ribatti D., Mohamadzadeh M., Luftig R. Setting the stage: an anatomist's view of the immune system. Trends Immunol 2004, 25:210-217.
25. Ingulli E., Ulman D.T., Lucido M.M., Jenkins M.K. In situ analysis reveals physical interactions between CD11b dendritic cells and antigen-specific CD4 T cells after subcutaneous injection of antigen. J Immunol 2002, 169:2247-2252.
26. Gourley T.S., Wherry E.J., Masopust D., Ahmed R. Generation and maintenance of immunological memory. Semin Immunol 2004, 16:323-333.
27. Moingeon P., Haensler J., Lindberg A. Towards the rational design of Th1 adjuvants. Vaccine 2001, 19:4363-4372.
28. Thomas-Kaskel A.K., Zeiser R., Jochim R., Robbel C., Schultze-Seeman W., Waller C.F., et al. Vaccination of advanced prostate cancer patients with PSCA and PSA peptide-loaded dendritic cells induces DTH responses that correlate with superior overall survival. Int J Cancer 2006, 119:2428-2434.
29. De Vries I.J.M., Bernsen M.R., Lesterhuis W.J., Scharenborg N.M., Strijk S.P., Gerritsen M.-J.P., et al. Immunomonitoring tumor-specific T cell in delayed-type-hypersensitivity skin biopsies after dendritic cell vaccination correlates with clinical outcome. J Clin Oncol 2005, 23:5779-5787.
30. Simeckova-Rosenberg J., Yun Z., Wyde P.R., Atassi M.Z. Protection of mice against lethal viral infection by synthetic peptides corresponding to B and T cell recognition sites of influenza A hemagglutinin. Vaccine 1995, 13:627-932.
31. Peoples G.E., Gurney J.M., Hueman M.T., Woll M.M., Ryan G.B., Storrer C.E., et al. Clinical trial results of a HER2/neu (E75) vaccine to prevent recurrence in high-risk breast cancer patients. J Clin Oncol 2005, 23:7536-7545.
32. Perambakam S., Hallmeyer S., Reddy S., Mahmud N., Bressler L., DeChristopher P., et al. Induction of specific T cell immunity in patients with prostate cancer by vaccination with PSA146-154 peptide. Cancer Immunol Immunother 2006, 55:1033-1042.
33. Jager E., Gnjatic S., Nagata Y., Stockert E., Jager D., Karbach J., et al. Induction of primary NY ESO-1 immunity: CD8+ T lymphocyte and antibody responses in peptide-vaccinated patients with NY ESO-1+ cancers. PNAS 2000, 97:12198-12203.
34. Whiteside T.W., Czystowska M., Han J., Szczepanski M.J., Szajnik M., Quadrini K., et al. IRX-2, a novel immunotherapeutic, protects human T cells from tumor-induced cell death. Cell Death Differ 2009, 16:708-718.